ACM
CRSP icon

Alpha Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Alpha Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,803
Closed -$1.35M – 119
2025
Q4 		$1.35M Buy
25,803
+17,718
+219% +$1.06M 0.19% 73
2025
Q3 		$524K Buy
+8,085
New +$464K 0.08% 93
2025
Q2 		– Sell
-12,223
Closed -$416K – 117
2025
Q1 		$416K Buy
+12,223
New +$518K 0.08% 94
2024
Q3 		– Sell
-36,636
Closed -$1.98M – 113
2024
Q2 		$1.98M Sell
36,636
-7,610
-17% -$440K 0.39% 65
2024
Q1 		$3.02M Sell
44,246
-492
-1% -$35.2K 0.59% 63
2023
Q4 		$2.8M Sell
44,738
-1,411
-3% -$78K 0.58% 62
2023
Q3 		$2.09M Buy
46,149
+13,208
+40% +$682K 0.49% 66
2023
Q2 		$1.34M Hold
32,941
– – 0.33% 74
2023
Q1 		$1.34M Hold
32,941
– – 0.33% 74
2022
Q4 		$1.34M Buy
32,941
+2,823
+9% +$150K 0.33% 74
2022
Q3 		$1.97M Buy
30,118
+3,213
+12% +$233K 0.52% 67
2022
Q2 		$1.64M Buy
26,905
+3,581
+15% +$211K 0.45% 68
2022
Q1 		$1.46M Buy
23,324
+852
+4% +$53.5K 0.32% 73
2021
Q4 		$1.7M Sell
22,472
-2,419
-10% -$211K 0.38% 70
2021
Q3 		$2.79M Sell
24,891
-569
-2% -$71.5K 0.66% 54
2021
Q2 		$4.12M Buy
25,460
+17,118
+205% +$2.08M 0.97% 30
2021
Q1 		$1.02M Buy
8,342
+3,164
+61% +$478K 0.26% 79
2020
Q4 		$793K Buy
+5,178
New +$612K 0.2% 79

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Alpha Capital Management's CRSP Position: Q1 2026 in Review

Alpha Capital Management sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 25,803 shares — an estimated $1.35M sold.

Alpha Capital Management first reported a position in CRSP in Q4 2020 and held it in 18 quarters. The position peaked at $4.12M in Q2 2021. 492 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Alpha Capital Management reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Alpha Capital Management sold 25,803 CRISPR Therapeutics shares in Q1 2026, an estimated $1.35M.
  • Alpha Capital Management first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 18 quarters.
  • Alpha Capital Management's CRISPR Therapeutics position peaked at $4.12M in Q2 2021.
  • 492 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Alpha Capital Management's 13F filing for Q1 2026, filed 13 May 2026.